Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating

Viking Therapeutics, Inc. (NASDAQ:VKTX) ranks among the best short squeeze stocks to buy right now. On November 20, H.C. Wainwright retained its Buy rating and $102 price target for Viking Therapeutics, Inc. (NASDAQ:VKTX) following the end of enrollment in the company’s VANQUISH-1 obesity trial. Copyright: dolgachov / 123RF Stock Photo The trial, which enrolled around 4,650 individuals, concluded ahead of schedule and will compare three different doses to a placebo over a 78-week period. VANQUISH-2, the ...